Prograf and Meningococcal sepsis - a phase IV clinical study of FDA data

Summary:

Meningococcal sepsis is reported only by a few people who take Prograf.

The phase IV clinical study analyzes which people take Prograf and have Meningococcal sepsis. It is created by eHealthMe based on reports of 39,863 people who have side effects while taking Prograf from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Mar, 28, 2023

39,863 people reported to have side effects when taking Prograf.
Among them, 2 people (0.01%) have Meningococcal sepsis.

What is Prograf?

Prograf has active ingredients of tacrolimus. It is often used in kidney transplant. eHealthMe is studying from 40,362 Prograf users for its effectiveness, alternative drugs and more.

What is Meningococcal sepsis?

Meningococcal sepsis (meningococcal infection to whole body) is found to be associated with 137 drugs and 72 conditions by eHealthMe.

Number of Prograf and Meningococcal sepsis reports submitted per year:

Could Prograf cause Meningococcal sepsis?

Gender of people who have Meningococcal sepsis when taking Prograf *:

female: 100 %
male: 0.0 %

Age of people who have Meningococcal sepsis when taking Prograf *:

Common drugs people take besides Prograf *:

Tacrolimus: 1 person, 50.00%
Plan B One-Step: 1 person, 50.00%
Mycophenolate Mofetil: 1 person, 50.00%
Fish Oil: 1 person, 50.00%
Cellcept: 1 person, 50.00%

Common side effects people have besides Meningococcal sepsis *:

Menstruation Irregular: 1 person, 50.00%

Common conditions people have *:

Haemolytic Uraemic Syndrome (blood clotting disease caused by e. coli infection, birth control pills, pneumonia, medications, and more): 2 people, 100.00%
Transient Ischaemic Attack (a transient episode of neurologic dysfunction caused by ischemia (loss of blood flow)): 1 person, 50.00%
Renal Osteodystrophy (a bone disease occurs when the kidneys fail to maintain the proper levels of calcium and phosphorus in the blood): 1 person, 50.00%

* Approximation only. Some reports may have incomplete information.

Do you take Prograf and have Meningococcal sepsis?

Check whether Meningococcal sepsis is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Meningococcal sepsis and when was it recovered:

Meningococcal sepsis in Prograf

Expand to all the drugs that have ingredients of tacrolimus:

Meningococcal sepsis and drugs with ingredients of tacrolimus

Alternative drugs to, pros and cons of Prograf:

Prograf (40,362 reports)

Common Prograf side effects:

Drug ineffective: 2,046 reports
Fever: 1,994 reports
Diarrhea: 1,800 reports
Pneumonia: 1,767 reports
Death: 1,751 reports
Acute kidney failure: 1,380 reports
Transplant rejection (a transplant material is not worked): 1,368 reports

Browse all side effects of Prograf:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Meningococcal sepsis treatments and more:

Meningococcal sepsis (320 reports)

COVID vaccines that are related to Meningococcal sepsis:

Common drugs associated with Meningococcal sepsis:

Soliris: 146 reports

All the drugs that are associated with Meningococcal sepsis:

Meningococcal sepsis (137 drugs)

All the conditions that are associated with Meningococcal sepsis:

Meningococcal sepsis (72 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on tacrolimus (the active ingredients of Prograf) and Prograf (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.